Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Successful commercialization and full capacity ramp of Kingsport molecular recycling operations, delivering mix-accretive circular polymers with above-average variable margins.
Severe feedstock spread compression in Chemical Intermediates combined with synchronized global industrial manufacturing stagnation.
We rate Eastman Chemical Company Buy with an intrinsic Fair value of $70.07, representing 11.4% upside from the analysis price of $62.88 as operating margins recover from cyclical lows.
The house rating is Buy. For an investor, this recommendation indicates an attractive opportunity to build exposure to a specialty materials leader as multi-year structural cost initiatives and operational volume improvements take hold.
Shares traded at $62.88 on $62.88 (as of 2026-10-14), standing at an appealing discount to our Fair value of $70.07 and well below our Potential value of $91.33. This gap provides 11.4% upside to the midpoint as cyclical earnings power normalizes.
The primary investment risk is prolonged macroeconomic weakness in Chemical Intermediates, where segment sales stood at $1,925 million in FY2025, combined with customer destocking across global end markets. If raw material and energy inflation outpace contract adjustments, consolidated operating margins could remain depressed below the 8.87% level recorded in FY2025.347
The central catalyst for value creation is the realization of $125 million to $150 million in affirmed net structural cost reductions for 2026, combined with the operational ramp of the Kingsport molecular recycling facility toward full capacity. Expanding high-margin recycled polymer output upgrades product mix and drives earnings toward consensus FY2027 diluted EPS of $6.79.14
Management affirmed delivery of $125 million to $150 million in net structural cost reductions for 2026, directly expanding operating margins from cyclical lows.4
Plant trials confirm operational capability to ramp Kingsport rPET to full capacity, delivering premium margin mix to Advanced Materials.4
Formulaic pass-through agreements cover raw material, energy, and logistics inflation, preserving market share and cash flow stability.4
We recommend a Buy rating because structural cost reductions and commercial scaling in circular specialty plastics provide 11.4% upside to our Fair value of $70.07.
Eastman Chemical Company is a global specialty materials producer that manufactures differentiated chemicals, fibers, and performance plastics. The company operates through four principal segments: Additives & Functional Products, Advanced Materials, Chemical Intermediates, and Fibers.
The company leverages integrated technology platforms across cellulosic biopolymer, acetyl, olefins, polyester, and alkylamine streams to manufacture high-value specialty products with cost-advantaged scale. Chemical Intermediates consumes key feedstock streams to support internal specialty operations while selling surplus intermediate chemicals into industrial, construction, and consumer packaging markets.
Eastman serves a diversified global customer base across transportation, building and construction, consumer goods, and agriculture, generating $3,662 million in domestic sales and $4,140 million across international markets in FY2025.
In a severe cyclical downturn, prolonged end-market weakness in Chemical Intermediates from Middle East logistics tensions combines with extended customer hesitation to build inventories. If technical line-out hurdles at Kingsport further delay commercial rPET volume shipments, consolidated operating margins remain depressed near FY2025's 8.87% level. Under these stress conditions, earnings per share would fail to reach the consensus FY2026 forecast of $6.35, testing downside valuation levels near $50.80.
Eastman Chemical Company possesses a Narrow economic moat underpinned by customer switching costs in formulated specialty additives and proprietary technology platforms in advanced circular polymers. The company's specialty portfolio is tightly integrated with customer manufacturing processes in high-specification end markets such as automotive interlayers, aviation fluids, and medical packaging, creating significant friction and qualification barriers for competing alternatives.
The competitive advantage is reinforced by cost advantages stemming from large-scale vertical integration across cellulosic biopolymer, acetyl, and olefins chemical streams. By supplying internal feedstock requirements to downstream specialty businesses at advantaged cost, Eastman protects variable margins while commercializing surplus intermediates in global merchant markets.
Pricing discipline and contractual cost pass-through mechanisms further defend the company's economic returns. During inflationary periods, formulaic pass-through agreements across specialty lines insulate earnings from raw material and energy cost surges without incurring market share losses.
Eastman's mid-cycle normalized returns on invested capital are positioned to exceed its moderate cost of equity of 9.63%, established via a risk-free rate of 5.21%, an of 4.20%, and an adjusted of 1.0535. While FY2025 of $776 million reflected cyclical trough conditions, economic profits are expected to expand as recover toward 11.0% to 12.0%.
The highlighted cell is Fair value when every assumption sits at its base level ($70.07). Each row and column shows what Fair value becomes when one assumption moves.
A free-cash-flow drop test is not available in this run; use the discount-rate and terminal-growth grid as the primary valuation pressure test.
A quarterly beat indicates accelerated operational absorption from structural cost reduction programs alongside rapid customer adoption of molecular recycling volumes, validating faster earnings normalization.
In-line execution demonstrates that affirmed net cost savings are being delivered as scheduled and that specialty pricing power remains intact despite ongoing macroeconomic caution.
The basic materials sector displays capital discipline, with industry capex-to-depreciation standing at 1.55 and industry capex-to-revenue at 4.1%, while industry operating margins average 12.4%. Eastman's own capital expenditure of $546 million aligned closely with depreciation of $513 million, demonstrating disciplined capacity additions.
An upturn driven by global industrial manufacturing reacceleration, end-market inventory restocking, and expanding price-cost spreads, propelling Eastman's operating margins above the industry benchmark of 12.4%.
A protracted cyclical downturn characterized by persistent high energy feedstocks, customer destocking, and weak building and construction demand, holding operating margins below 9.0%.
A moderate position weighting reflects the attractive upside toward our Fair value balanced against cyclical exposure in chemical intermediates and near-term line-out pacing in circular plastics.
Risk management centers on monitoring gross margin durability across raw material price cycles and verifying the execution of affirmed cost takeout milestones. Capital should be allocated in staggered tranches to mitigate downside from broader industrial manufacturing weakness, while portfolio exposure is capped within disciplined cyclical sector guidelines.
Eastman trades at an attractive valuation relative to normalized mid-cycle earnings power, providing 11.4% upside to Fair value as operating profit recovers.
Management's delivery on structural cost savings programs alongside pricing discipline provides clear operational leverage as customer order volumes normalize.
Proprietary molecular recycling infrastructure establishes a durable competitive moat in circular plastics, capturing high-margin premium demand over a multi-year horizon.
We recommend a Buy rating on Eastman Chemical Company. Shares traded at $62.88 on $62.88 (as of 2026-10-14), offering 11.4% upside to our Fair value of $70.07 and substantial long-term optionality toward Potential value of $91.33.
The investment thesis is driven by structural cost reductions, volume recovery across formulated specialty plastics, and margin expansion from commercial molecular recycling operations.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
The downside path contemplates extended industrial contraction, severe raw material spread compression, and delayed commercialization of molecular recycling assets. Under these conditions, customer destocking persists across domestic and foreign end markets while feedstock cost inflation erodes profitability in intermediate chemical chains. The reader would identify this path unfolding through declining segment volumes, persistent plant turnaround cost overruns, and an inability to maintain price discipline during contract renewals over the coming fiscal periods.
Energy headwinds and raw material inflation compress product spreads while utilizations remain depressed, exacerbated by Middle East logistics disruptions in Chemical Intermediates and $40M-$45M in quarterly turnaround headwinds, driving operating margins below FY2025's 8.87% EBIT level.34
Sluggish customer adoption in specialty packaging and weakness in Chemical Intermediates cause the market to re-rate Eastman toward commodity chemical peers like Albemarle at 8.7x rather than specialty multiples, compressing the terminal P/E from 11.0x.37
Management reports widespread macroeconomic weakness across both domestic and foreign markets with customers unwilling to build inventory, while Kingsport rPET line-out challenges constrain volume ramp, invalidating the projected FY2026 revenue rebound to $9.26B.147
The five developments that would weaken our investment case.
Operating margin fails to rebound into the 11.0% to 12.0% range, indicating structural cost savings of $125M-$150M are being absorbed by raw material inflation and turnaround costs.
Current:8.87% in FY2025
Alert ifBelow 9.0% in FY2026
Kingsport molecular recycling line-out issues persist and customer qualification stalls, failing to deliver the projected rPET volume recovery.
Current:$2,880 million in FY2025
Alert ifBelow $2,800 million in FY2026
Synchronous economic weakness across the United States ($3,662 million in FY2025) and foreign markets ($4,140 million in FY2025) prevents volume recovery.
Current:$8,752 million in FY2025
Alert ifBelow $8,500 million in FY2026
Persistent Middle East logistics conflicts and feedstock spread volatility suppress merchant acetyls and olefins revenue.
Current:$1,925 million in FY2025
Alert ifBelow $1,800 million in FY2026
Prolonged macroeconomic sluggishness and customer destocking in Asian export markets curtail regional volume shipments.
Current:$950 million in FY2025
Alert ifBelow $850 million in FY2026
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Under the moderate discount rate, $22.61 comes from forecast-period earnings and $69.30 from the long-term value, totaling $91.91.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
In the upside path, shares reach $91.33 with an estimated probability of 20.0%, offering an implied return of 45.2% from $62.88. This scenario requires global industrial activity to reaccelerate rapidly, lifting volume demand across specialty additives and advanced materials. Simultaneously, the Kingsport circular plastics platform must ramp seamlessly to full nameplate capacity, capturing premium mix pricing from major consumer brands. Disconfirmation would occur if quarterly volume growth stalls or if customer price increases are rolled back under peer competitive pressure by the middle of FY2027.
The modal path projects shares achieving $70.07 with an estimated probability of 55.0%, generating an implied return of 11.4% relative to $62.88. For this path to unfold, management must execute on affirmed structural cost savings programs while operational line-out progress at the Kingsport facility enables orderly volume expansion across FY2026 and FY2027. This path would be disconfirmed if operating margins fail to expand above cyclical trough levels or if customer destocking in chemical intermediates persists past the conclusion of FY2026.
A significant quarterly shortfall would indicate that cost takeouts are being overwhelmed by feedstock inflation or that mechanical bottlenecks at the circular recycling plant are worsening.
Earnings quality is supported by solid cash conversion through cyclical trough conditions, with operating cash flow continuing to exceed net income. Working capital management remains disciplined, and inventory balances are actively aligned with customer ordering patterns. High contractual cost pass-through coverage across formulated specialty lines reinforces gross margin durability, ensuring that reported earnings accurately reflect underlying operational performance rather than accounting accruals.
Consensus analyst revisions have stabilized following recent earnings disclosures, reflecting balanced expectations as affirmed structural cost savings offset near-term macroeconomic slowness.
Operating margin expansion reveals whether structural cost reductions are dropping to the bottom line or being consumed by input cost inflation, directly driving mid-cycle earnings power per share.
Operational ramp to full capacity demonstrates commercial viability of the circular technology, unlocking mix-accretive variable margins and lifting Advanced Materials profitability.
Spread health in acetyls and olefins indicates basic chemical supply-demand balance, driving segment cash generation and preventing negative earnings drag on specialty units.
Shifts from cautious hand-to-mouth purchasing toward order restocking reveal underlying industrial demand inflection, accelerating consolidated revenue growth.
Discretionary cash conversion funds capital reinvestment in circular assets and dividend coverage, reducing leverage and defending equity valuation.
| $10.48B |
| $10.58B |
| $9.21B |
| $9.38B |
| $8.75B |
| -4.4% |
| Gross profit | $2.50B | $2.14B | $2.06B | $2.29B | $1.84B | -7.3% |
| Operating income | $1.27B | $1.16B | $1.10B | $1.29B | $776.0M | -11.7% |
| Net income | $857.0M | $793.0M | $894.0M | $905.0M | $474.0M | -13.8% |
| EPS (diluted) | $6.25 | $6.35 | $7.49 | $7.67 | $4.10 | -10.0% |
| EBITDA | $1.81B | $1.64B | $1.59B | $1.80B | $1.29B | -8.2% |
| R&D | $254.0M | $264.0M | $239.0M | $250.0M | $255.0M | +0.1% |
| SG&A | $795.0M | $726.0M | $727.0M | $736.0M | $658.0M | -4.6% |
Eastman demonstrated resilient cash generation during cyclical trough conditions, producing $970 million in operating cash flow and $424 million in free cash flow in FY2025. Operating income reached $931 million, supporting ongoing capital expenditure of $546 million against depreciation of $513 million. As management delivers on $125 million to $150 million in affirmed net structural cost reductions for 2026 and working capital needs stabilize, operating cash conversion is expected to strengthen meaningfully.3456
Eastman maintains a disciplined, shareholder-focused capital allocation framework. Historically, management deployed capital into synergistic specialty acquisitions such as Solutia and Taminco at disciplined valuations around 9x EBITDA. The current strategy emphasizes organic growth investments, notably scaling the Kingsport circular facility toward 100% capacity, alongside sustaining a reliable common dividend and executing opportunistic share repurchases as diluted shares outstanding stood at 115.6 million at year-end FY2025.
Return on invested capital is troughing following cyclical margin compression in FY2025 where EBIT was $776 million. ROIC is projected to expand steadily over the five-year forecast horizon as operating margins expand from 8.87% toward 12.0% on structural cost takeouts and higher circular specialty plant utilization.
Normalized mid-cycle ROIC is projected to comfortably exceed Eastman's moderate cost of equity of 9.63%, derived from a 5.21% risk-free rate, 4.20% equity risk premium, and 1.0535 adjusted beta, confirming positive economic value added across the cycle.
Management affirmed delivery on $125 million to $150 million in net structural operating expense reductions for 2026.
The cost takeout drops directly to operating profit, providing a baseline margin uplift that does not depend on immediate volume expansion.
Kingsport molecular recycling facility variable margins are above corporate average, with tests demonstrating capability to ramp toward 100% capacity.
Volume growth in Advanced Materials will carry higher incremental margins, accelerating free cash flow expansion above historical mid-cycle rates.
Disciplined pricing adjustments implemented in July covered raw material, energy, and logistics inflation with no market share loss.
Operating cash flow remains insulated from short-term chemical commodity volatility, ensuring capital expenditure funding integrity.
| Revenue | $2,513,000,000 |
|---|---|
| Cost of revenue | $1,953,000,000 |
| Gross profit | $560,000,000 |
| Operating expenses | $250,000,000 |
| Operating income | $310,000,000 |
| Non-operating items and tax | -$127,000,000 |
| Net income | $183,000,000 |
| Total assets | $14,859,000,000 |
|---|---|
| Cash | $566,000,000 |
| Current assets | $3,645,000,000 |
| Total liabilities | $8,822,000,000 |
| Current liabilities | $2,652,000,000 |
| Shareholders’ equity | $6,037,000,000 |
| Net income | $474,000,000 |
|---|---|
| Operating inflow | $987,000,000 |
| Depreciation and amortization | $513,000,000 |
| Operating cash flow | $970,000,000 |
| Operating outflow | $17,000,000 |
| Cash available | $1,825,000,000 |
| Beginning cash | $837,000,000 |
| Exchange-rate effect | $18,000,000 |
| Investing outflow | $462,000,000 |
| Financing outflow | $797,000,000 |
| Share repurchases | $100,000,000 |
| Dividends paid | $381,000,000 |
| Net debt repayment | $304,000,000 |
| Other financing activities | $12,000,000 |
| Ending cash | $566,000,000 |
| Investing cash flow | -$462,000,000 |
| Financing cash flow | -$797,000,000 |
Source: SEC EDGAR · Filed 2026-02-13 · SEC EDGAR
| Revenue by operating segment | Revenue | Share | YoY |
|---|---|---|---|
| Additives And Functional Products | $2.9B | 32.9% | 0.6% |
| Advanced Materials | $2.9B | 32.9% | -5.6% |
| Chemical Intermediates | $1.9B | 22% | -9.8% |
| Fibers | $1.1B | 12% | -20.3% |
Source: SEC EDGAR · Filed 2026-02-13 · SEC EDGAR
| Revenue by geography | Revenue | Share | YoY |
|---|---|---|---|
| All Foreign | $4.1B | 47.3% | -8.7% |
| United States | $3.7B | 41.8% | -2.9% |
| China | $950M | 10.9% | -11.5% |
Point-in-time financial data used in the 2026-10-15 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $9B | $1.9B | $854M | $1.4B | $759M | $626M | $580M | $36M | — | $272M | — | -$655M | -$838M | — | $181M | $182M | $6.6B | 15.4% | — | 6.1% | — |
| 2017-12-31 | $9.5B | $2.1B | $1.4B | $1.7B | $1B | $649M | $587M | $52M | — | $296M | — | -$643M | -$1B | $181M | $191M | $192M | $6.5B | 16.0% | — | 5.9% | — |
| 2018-12-31 | $10.2B | $2.1B | $1.1B | $1.5B | $1B | $528M | $604M | $64M | — | $318M | — | -$463M | -$1B | $191M | $226M | $227M | $6.2B | 14.5% | — | 5.8% | — |
| 2019-12-31 | $9.3B | $1.7B | $759M | $1.5B | $1.1B | $425M | $611M | $96M | — | $343M | — | -$480M | -$1B | $226M | $204M | $205M | $5.8B | 14.3% | — | 5.4% | — |
| 2020-12-31 | $8.5B | $1.3B | $478M | $1.5B | $1.1B | $383M | $574M | $387M | — | $358M | — | -$394M | -$704M | $204M | $564M | $565M | $5.6B | 13.3% | — | 5.1% | — |
| 2021-12-31 | $10.5B | $1.8B | $857M | $1.6B | $1.1B | $555M | $538M | $302M | $900M | $375M | — | -$29M | -$1.7B | $564M | $459M | $485M | $5.5B | 14.0% | — | 5.7% | — |
| 2022-12-31 | $10.6B | $1.6B | $793M | $975M | $364M | $611M | $477M | -$103M | $1B | $381M | $76M | $392M | -$1.3B | $459M | $493M | $494M | $5.2B | 10.2% | — | 7.7% | — |
| 2023-12-31 | $9.2B | $1.6B | $894M | $1.4B | $546M | $828M | $498M | $65M | $150M | $376M | -$338M | -$432M | -$888M | $493M | $548M | $549M | $5.1B | 11.9% | — | 8.0% | — |
| 2024-12-31 | $9.4B | $1.8B | $905M | $1.3B | $688M | $599M | $509M | $99M | $300M | $379M | $198M | -$534M | -$454M | $548M | $837M | $837M | $5.3B | 14.7% | — | 8.5% | — |
| 2025-12-31 | $8.8B | $1.3B | $474M | $970M | $424M | $546M | $513M | — | $100M | $381M | -$304M | -$462M | -$797M | $837M | $566M | $566M | $5.1B | 10.6% | — | 7.4% | — |
Eastman Chemical Company (EMN) trades at 9.2x forward earnings against a peer median of 14.1x. Its EV/EBITDA of 8.6x compares with a peer median of 11.4x. The comparison uses 4 peers: DuPont de Nemours Inc., Albemarle Corporation, International Flavors & Fragrances Inc. and PPG Industries Inc., as of 2026-10-15.
Eastman is strategically positioned as a differentiated specialty producer with 41.8% of FY2025 revenues generated in the United States and 47.3% across international markets. Its contractual pass-through structures and proprietary molecular recycling platform allow it to defend margins better than pure commodity peers.47
| Initiate Primary Tranche |
| Establish initial position at $62.88 as share prices trade at a meaningful discount offering 11.4% upside to Fair value. |
| Extended pullback | Accumulate Secondary Tranche | Deploy additional capital on extended pullbacks, securing an expanded margin of safety against cyclical intermediate volatility. |
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Project revenue, apply a terminal EV/revenue multiple, discount enterprise value, subtract net debt, and divide by diluted shares.
| Albemarle Corporation |
| $11.6B |
| 8.7x |
| 2.0x |
| 9.7x |
| 2.6% |
| 27.7% |
| IFF | International Flavors & Fragrances Inc. | $22.9B | 22.6x | 2.1x | 15.0x | -5.5% | 8.5% |
| PPG | PPG Industries Inc. | $23.3B | 12.2x | 1.4x | 10.9x | 19.3% | 14.0% |
